Brief: Lexicon Submits New Data to FDA Supporting Zynquista’s Use in Type 1 Diabetes

Lexicon Pharmaceuticals

08/09/2025 13:40

Sept 8 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:

LEXICON PHARMACEUTICALS ANNOUNCES SUBMISSION OF ADDITIONAL DATA TO U.S. FDA SUPPORTING THE BENEFIT-RISK PROFILE OF ZYNQUISTA® IN TYPE 1 DIABETES

LEXICON PHARMACEUTICALS INC - FDA FEEDBACK FROM TYPE D MEETING EXPECTED BY END OF SEPTEMBER

Source text: ID:nGNX6VThk9

Further company coverage: LXRX.O

 ((Reuters.Briefs@thomsonreuters.com;))